[1] Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183:109119. [2] Ma RCW. Epidemiology of diabetes and diabetic complications in China[J]. Diabetologia, 2018, 61(6):1249-1260. [3] Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation[J].Cardiovasc Diabetol, 2018, 17(1):57. [4] Martínez-Castelao A, Navarro-González JF, Górriz JL, et al. The concept and the epidemiology of diabetic nephropathy have changed in recent years[J]. J Clin Med, 2015, 4(6):1207-1216. [5] Zakin E, Abrams R, Simpson DM. Diabetic neuropathy[J]. Semin Neurol, 2019, 39(5):560-569. [6] Faselis C, Katsimardou A, Imprialos K, et al. Microvascular complications of type 2 diabetes mellitus[J]. Curr Vasc Pharmacol, 2020, 18(2):117-124. [7] Khan F, Tritschler T, Kahn SR, et al. Venous thromboembolism[J]. Lancet, 2021, 398(10294):64-77. [8] Strijkers RH, Cate-Hoek AJ, Bukkems SF, et al. Management of deep vein thrombosis and prevention of post-thrombotic syndrome[J]. BMJ, 2011, 343:d5916. [9] Lv B, Hu L, Fang H, et al. Development and validation of a nomogram incorporating colloid osmotic pressure for predicting mortality in critically ill neurological patients[J]. Front Med(Lausanne), 2021, 8:765818. [10] Ye JZ, Mai RY, Guo WX, et al. Nomogram for prediction of the international study Group of Liver Surgery (ISGLS) grade B/C Posthepatectomy liver failure in HBV-related hepatocellular carcinoma patients: an external validation and prospective application study[J]. BMC Cancer, 2020, 20(1):1036. [11] Ferrannini G, Manca ML, Magnoni M, et al. Coronary artery disease and type 2 diabetes:a proteomic study[J]. Diabetes Care, 2020, 43(4):843-851. [12] Stone J, Hangee P, Albadawl H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management[J]. Cardiovasc Diagn Ther, 2017, 7(suppl 3):S276-S284. [13] Chopard R, Albertsen IE, Piazza G. Diagnosis and treatment of lower extremity venous thromboembolism: a review[J]. JAMA, 2020, 324(17):1765-1776. [14] Al-Sofiani ME, Ganji SS, Kalyani RR. Body composition changes in diabetes and aging[J].J Diabetes Complications, 2019, 33(6):451-459. [15] Shou J, Chen PJ, Xiao WH. Mechanism of increased risk of insulin resistance in aging skeletal muscle[J]. Diabetol Metab Syndr, 2020, 12:14. [16] Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications[J]. Diabetes Metab J, 2018, 42(3):188-195. [17] Brownlee M. Biochemistry and molecular cell biology of diabetic complications[J]. Nature, 2001, 414(6865):813-820. [18] 张琳, 杨秋萍, 吴亚楠, 等. 老年2型糖尿病患者下肢深静脉血栓形成的相关危险因素[J]. 中国老年学杂志,2011,31(15):2817-2820. [19] Tritschler T, Kraaijpoel N, Le Gal G, et al. Venous thromboembolism: advances in diagnosis and treatment[J]. JAMA, 2018, 320(15):1583-1594. [20] Folsom AR, Lutsey PL, Astor BC, et al. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort[J]. Thromb Haemost, 2009, 102(4):615-619. [21] Branchford BR, Carpenter SL. The role of Inflammation in venous thromboembolism[J].Front Pediatr, 2018, 23(6): 142. |